The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Open accessAbstract
PURPOSE: The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk. PATIENTS AND METHODS: Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up. RESULTS: Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8%; P=0.003). Women aged <50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36%; P=0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95% CI 0.30-0.76; P=0.002). CONCLUSION: The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We observed that family history is a predictor of CBC risk in both noncarriers and mutation carriers, which is in line with previous literature.19,21”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers (2016) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
Self-citationRebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Self-citationContralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 620 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundSelf-citationSurvival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundEisen, A. F., Lubiński, J., Klijn, J. G. M., Møller, P., Lynch, H. T., Offit, K., Weber, B., Rebbeck, T., Neuhausen, S. L., Ghadirian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.7138 · Cited by 442
Self-citationContralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundOutcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundBRCA-associated breast cancer in young women.
Robson, M. E., Gilewski, T., Haas, B. R., Levin, D. R., Borgen, P. I., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., LESSER, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 303 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
BackgroundTamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M. B., Kim‐Sing, C., Olsson, H. L., Ainsworth, P., Eisen, A. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21536 · Cited by 253
Self-citationBrekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · cited 1×
“…lifetime risk of breast cancer (Ford et al, 1998) and, once diagnosed with breast cancer, face a high risk of second primary cancer in the contralateral breast (Robson et al, 1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al, 2004; Brekelmans et al, 2007; Graeser et al, 2009).”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 232
Ye, F., Huang, L., Lang, G., Hu, X., Di, G., Shao, Z., & Cao, A. (2020) · Cancer Medicine · doi:10.1002/cam4.2836 · Cited by 15
Huang, H., Couch, R. E., Karam, R., Hu, C., Boddicker, N. J., Polley, E. C., Na, J., Ambrosone, C. B., Yao, S., Trentham‐Dietz, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1884 · Cited by 14
Self-citationThe molecular and clinicopathologic characteristics of bilateral breast cancer
Chen, S., Du, C., Yang, P., Zhang, H. W., Kwan, M. L., & Zhang, G. J. (2013) · Scientific Reports · doi:10.1038/srep02590 · Cited by 14
Contralateral risk reducing mastectomy in patients with sporadic breast cancer. Benefits and hazards
Boccardo, C., & Gentilini, O. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.04.054 · Cited by 14
Yoon, K.-H., Chae, S., Kang, E., Shin, H.-C., Kim, J. H., Kim, I. A., Park, S. Y., Kim, S., & Kim, E. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e47 · Cited by 14
“Younger age at the time of first breast cancer diagnosis is reported to be associated with a higher risk of CBC in patients with a BRCA mutation [6,13].”
BackgroundResultInfluentialHosoya, N., & Miyagawa, K. (2021) · Journal of Radiation Research · doi:10.1093/jrr/rrab009 · Cited by 13
Khan, H. Z., Labanca, F., Ullah, H., Hussain, Y., Tzvetkov, N. T., Akkol, E. K., & Milella, L. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-021-09771-3 · Cited by 13
Ro, V., McGuinness, J. E., Guo, B., Trivedi, M. S., Jones, T., Chung, W. K., Rao, R., Levinson, E., Koval, C., Russo, D., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00322 · Cited by 13
Reid, S., Cragun, D. L., Tezak, A. L., Weidner, A. E., Moore, J., Mayer, I. A., Shu, X., Ye, F., Fan, R., Vadaparampil, S. T., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0762-0 · Cited by 13
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Abouharb, S., & Litton, J. K. (2012) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2012.03.011 · Cited by 13
Nasedkina, T. V., Громыко, О. Е., Emelyanova, M., Ignatova, E., Kazubskaya, T. P., Портной, С. М., Заседателев, А. С., & Lyubchenko, L. N. (2014) · Molecular Biology · doi:10.1134/s0026893314020149 · Cited by 12
Dagan, E., Birenbaum‐Carmeli, D., Friedman, E., & Feldman, B. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0087-6 · Cited by 12
“Data analysis was performed both inductively and recursively, using the phenomenological paradigm (Moustakas 1994) to unveil preferences and motives to opt for and follow PGD for BRCA1/2 screening, or to refrain from doing so.”
BackgroundMethodBRCA Variations Risk Assessment in Breast Cancers Using Different Artificial Intelligence Models
Şentürk, N., Tuncel, G., Doğan, B., Aliyeva, L., Dündar, M. S., Sağ, Ş. Ö., Mocan, G., Temel, Ş. G., Dündar, M., & Ergören, M. Ç. (2021) · Genes · doi:10.3390/genes12111774 · Cited by 11
“These women have a higher risk of having a second ipsilateral [17] or contralateral [18] breast cancer after being diagnosed with invasive breast cancer.”
Backgroundvan Barele, M., Akdeniz, D., Heemskerk‐Gerritsen, B. A. M., Genepso, Andrieu, N., Noguès, C., HEBON, van Asperen, C. J., Wevers, M. R., Ausems, M. G. E. M., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad116 · Cited by 11
How does genome sequencing impact surgery?
Reimers, M. S., Engels, C. C., Kuppen, P. J. K., van de Velde, C. J. �., & Liefers, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.101 · Cited by 11
The risk of contralateral breast cancer in daughters of women with and without breast cancer
Narod, S. A., Kharazmi, E., Fallah, M., Sundquist, K., & Hemminki, K. (2015) · Clinical Genetics · doi:10.1111/cge.12604 · Cited by 11
Self-citationEvron, E., Ben-David, M. A., Kaidar‐Person, O., & Corn, B. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01609 · Cited by 12
Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection
Martelli, G., Barretta, F., Vernieri, C., Folli, S., Pruneri, G., Segattini, S., Trapani, A., Carolla, C., Spatti, G., Miceli, R., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.4770 · Cited by 10
Varga, E., Chao, E., & Yeager, N. D. (2015) · Familial Cancer · doi:10.1007/s10689-015-9790-3 · Cited by 10
“Genetic testing is relevant for his at risk relatives, including his sister who was diagnosed at 41 with breast cancer, since studies suggest that woman with BRCA2 mutations have an increased risk of contralateral breast cancer in the absence of intervention [15] and that the risk of ovarian, primary peritoneal and fa…”
BackgroundWevers, M. R., Schou‐Bredal, I., Verhoef, S., Bleiker, E. M. A., Hahn, D. E. E., Brouwer, T., Kieffer, J. M., Ausems, M. G. E. M., & Aaronson, N. K. (2020) · Journal of Psychosocial Oncology Research and Practice · doi:10.1097/or9.0000000000000018 · Cited by 10
Bando, H. (2013) · Breast Cancer · doi:10.1007/s12282-013-0477-z · Cited by 9
Pacelli, R., Conson, M., Cella, L., Liuzzi, R., Troncone, G., Iorio, V., Solla, R., Farella, A., Scala, S., Pagliarulo, C., et al. (2012) · Journal of Radiation Research · doi:10.1093/jrr/rrs087 · Cited by 9
“However, it must be remarked that in the basal type subset of patients there is a higher proportion of BRCA-1 and -2 mutant patients [20], and that BRCA-1 and -2 mutant patients carry a high risk of CBC [21].”
BackgroundNomogram to predict contralateral breast cancer risk in breast cancer survivors
Tong, J., Tan, D., Ma, J., Hu, Y., & Li, M. (2021) · Medicine · doi:10.1097/md.0000000000027595 · Cited by 8
“The lifetime risk of BC and of CBC for women who carry a BRCA mutation is very high.([30]) Reiner et al have also demonstrated that women with a family history of BC have a higher risk of CBC even after a negative BRCA result.”
BackgroundA study of clinical and molecular characteristics in bilateral primary breast cancer
Li, B., Xu, W., Cao, J., Guo, D., Tao, Z., Jin, J., & Hu, X. (2023) · Cancer Medicine · doi:10.1002/cam4.6226 · Cited by 8
Breast Cancer Prevention Across the Cancer Care Continuum
Klemp, J. R. (2015) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2015.03.002 · Cited by 9
Day, S., & Bevers, T. B. (2013) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2013.07.020 · Cited by 8
Early-Onset Breast Cancer: What do We Know about the Risk Factors?
Narod, S. A. (2011) · Current Oncology · doi:10.3747/co.v18i5.938 · Cited by 8
Self-citationThe impact of the Biomolecular Era on breast cancer surgery
McVeigh, T. P., Boland, M. R., & Lowery, A. (2016) · The Surgeon · doi:10.1016/j.surge.2016.09.007 · Cited by 8
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant
Apostol, A. I., Kotsopoulos, J., Gronwald, J., Kim, R. H., Karlan, B. Y., Aeilts, A. M., y Cajal, T. R., Pal, T., Eisen, A. F., Bordeleau, L. J., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.07.030 · Cited by 7
Self-citationZambelli, A., Cortesi, L., Gaudio, M., Arpino, G., Bianchini, G., Caruso, F., Cinieri, S., Curigliano, G., Mastro, L. D., Placido, S. D., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102815 · Cited by 8
Familiärer Brustkrebs – empirische Erkrankungsrisiken und Risikoberechnungsmodelle
Engel, C., Zachariae, S., & Fischer, C. (2015) · Medizinische Genetik · doi:10.1007/s11825-015-0043-5 · Cited by 8
A Comprehensive Approach to the Identification and Management of the BRCA Patient
Garcia, C., & Powell, C. B. (2015) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000156 · Cited by 7
Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
Pellegrino, B., Bella, M., Michiara, M., Zanelli, P., Naldi, N., Porzio, R., Bortesi, B., Boggiani, D., Zanoni, D., Camisa, R., et al. (2016) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 7
Optimal surgical management for high-risk populations
King, T. A., Pilewskie, M. L., & Morrow, M. (2015) · The Breast · doi:10.1016/j.breast.2015.07.022 · Cited by 7
“[54] demonstrated that age >50 years at diagnosis was associated with decreased risk of CBC at 15 years compared to age at diagnosis <50 years (16.”
BackgroundRisk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer
Green, L., & Meric‐Bernstam, F. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0047-3 · Cited by 7
“008).[9] The cumulative risk of CBC at 5, 10 and 15 years was 14.”
BackgroundInfluentialSilva, S. D., Tennekoon, K. H., Dissanayake, A., Silva, K. D., & Jayasekara, L. M. D. T. (2016) · Familial Cancer · doi:10.1007/s10689-016-9962-9 · Cited by 7
Thomssen, C., Scharl, A. J., & Harbeck, N. (2011) · Breast Care · doi:10.1159/000331459 · Cited by 7
Maksimenko, J., Rodrigues, P. P., Nakazawa-Miklaševiča, M., Pinto, D., Miklaševičs, E., Trofimovičs, G., Gardovskis, J., Cardoso, F., & Cardoso, M. J. (2022) · JMIR Formative Research · doi:10.2196/37144 · Cited by 6
“Multiple studies showed that a younger age at the onset of first breast cancer is associated with a higher contralateral breast cancer risk [23-26].”
Kang, E. K., Jung, J.-J., Lim, C., Kim, H. K., Lee, H., Han, W., & Moon, H. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01769-x · Cited by 6
“Studies of populations in the USA or Europe have shown that BRCA1 and BRCA2 mutations have a 24–35% and 19–29% risk of developing contralateral breast cancer within 10 years of their first breast cancer [8, 31–33].”
BackgroundDagan, E., Gershoni‐Baruch, R., Kurolap, A., & Fried, G. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12594 · Cited by 6
Who should get a contralateral prophylactic mastectomy for breast cancer?
Bedrosian, I., Parker, P. A., & Brewster, A. M. (2019) · Cancer · doi:10.1002/cncr.31915 · Cited by 5
“The number of other affected family members in this scenario and the tumor subtype further impact CBC risk for such a patient.(4,5) However, there are no models incorporating all of these key riskassociated variables to allow for an accurate estimate of CBC risk.”
BackgroundCarneiro, V. C. G., Gifoni, A. C. L. V. C., Rossi, B. M., Andrade, C. E. M. D. C., de Lima, F. T., Galvão, H. D. C. R., da Rocha, J. C. C., Barreto, L. S. D. S., Ashton‐Prolla, P., Guindalini, R. S. C., et al. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26812 · Cited by 5
Wan, Q., Hu, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., Xu, Y., & Xie, Y. (2020) · Familial Cancer · doi:10.1007/s10689-020-00202-4 · Cited by 5
Inuzuka, M., Watanabe, C., Yokoyama, S., Kuwayama, T., Akashi‐Tanaka, S., Arai, M., Nakamura, S., Nakamura, S., Enomoto, T., Nomizu, T., et al. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.08.004 · Cited by 5
Strategies to enhance identification of hereditary breast cancer gene carriers
Reid, S., Spalluto, L. B., & Pal, T. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1816829 · Cited by 5
Surgery and prophylactic surgery in hereditary breast cancer
Morrow, M. (2021) · The Breast · doi:10.1016/j.breast.2021.12.010 · Cited by 5
“7% of those 50 years at initial diagnosis [13].”
BackgroundGoel, V., Sharma, D., Sharma, A., & Mallick, S. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.09.007 · Cited by 4
Myers, S. P., Tadros, A. B., Sevilimedu, V., Nelson, J. A., Le, T., Garcia, P., Morrow, M., & Lee, M. K. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14086-y · Cited by 4
Ghosh, R., Pfeiffer, R. M., Roberts, S., Gierach, G. L., & Dallal, C. M. (2024) · Cancer Causes & Control · doi:10.1007/s10552-024-01900-5 · Cited by 4
“Sensitivity analyses were conducted excluding studies that (1) reported risk estimates among BRCA1/2 mutation carriers [18, 22, 29, 36] and (2) assessed low-dose tamoxifen use [31].”
InfluentialLes indications des reconstructions mammaires après mastectomie selon la situation carcinologique
Mathelin, C., & Bruant-rodier, C. (2018) · Annales de Chirurgie Plastique Esthétique · doi:10.1016/j.anplas.2018.09.003 · Cited by 4
Purnomosari, D., Raharjo, C. A., Kalim, A. S., Herviastuti, R., Yushan, M., Fajar, R., Harris, K. K., & Wahyono, A. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.11.3305 · Cited by 4
“Early onset ofBC tends to occur with hormone receptor negativity in larger and more aggressive, high grade tumors with hormone receptor negativity, and HER2 overexpression (Assi et al., 2013), with greater risk of contralateral breast cancer in 15 years (Metcalfe et al., 2011).”
BackgroundModifiable and Nonmodifiable Risk Factors for Breast Cancer: A Comprehensive Scoping Review
Momenimovahed, Z., Shahabinia, Z., Allahqoli, L., & Salehiniya, H. (2026) · International Journal of Breast Cancer · doi:10.1155/ijbc/8689986 · Cited by 3
“Studies have indicated that the association of breast cancer in women with a first-and second-degree family history is stronger than that in those with no family history [15, 16].”
Tonouo, P. D., Bell, E. D., Tiofack, A. A. Z., Ndounga, E., Ananga, S. N., Atenguena, E., Simo, G., Njouendou, A. J., & Lueong, S. (2022) · Medical Oncology · doi:10.1007/s12032-022-01877-8 · Cited by 3
“Furthermore, although mutations in high penetrance genes such as BRCA1 and BRCA2 are associated with very high risk of contralateral breast cancer, these mutations are only seen in a small fraction of patients with EOBRCA [6, 7].”
BackgroundTorres, S., Peleteiro, B., Magalhães, A., Garrido, L., Costa, S., & Fougo, J. L. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04663-9 · Cited by 4
“P/LP variants in BRCA1 confer a higher risk for breast cancer compared to P/LP variants in BRCA2 (Saslow et al.”
BackgroundInfluentialRecurrence Patterns and Long-Term Results After Curative Surgery for Patients With Breast Cancer
Yang, Z. F., Wu, T., Chen, P., Li, L., Leng, K., Dong, R., & Shi, G. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16726-3 · Cited by 3
“57 Hence, the utilization of BCT for patients with SBC necessitates thoughtful deliberation and individualized decision-making strategies in clinical practice.”
Cabañuz, M. A., Bretón, M. D., Ezquerro, J. C., del Amo, M. D. A., & Sánchez, A. T. G. (2020) · Cirugía Española · doi:10.1016/j.ciresp.2020.04.008 · Cited by 3
The EUSOMA recommendations for the management of young women with breast cancer
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F. A., Delaloge, S., Marotti, L., et al. (2012) · Cited by 3
Dagan, E., Gershoni‐Baruch, R., Kurolap, A., Goldberg, Y., & Fried, G. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2013.0513 · Cited by 3
“BRCA1/2 carriers more often present with early-onset breast–ovarian cancer (see review by Robson, 2004) and bilateral breast cancer (Metcalfe et al. , 2011a, 2011b).”
Metcalfe, K. A., Eisen, A. F., Wright, F. C., Poll, A., Candib, A., McCready, D. R., Cil, T. D., Armel, S. R., Silberman, Y., Brennenstuhl, S., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06457-4 · Cited by 3
“Bilateral mastectomy has been shown to reduce the risk of contralateral breast cancer for women with a BRCA1 or BRCA2 mutation by 97% [2, 4].”
BackgroundSelf-citationLammert, J., Basrai, M., Struck, J., Hartmann, O., Engel, C., Bischoff, S. C., Berling-Ernst, A., Halle, M., Kiechle, M. B., & Grill, S. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1811-2164 · Cited by 3
“They also have a high risk of developing contralateral [24] or ipsilateral cancer [25].”
Second Malignant Neoplasms in Pediatric Oncology Patients: A Single Center Experience
Tanyıldız, H. G., Yeşil, Ş., Tekgündüz, S. A., Candir, M. O., Toprak, Ş., Bozkurt, C., Yüksek, N., Şahin, G., & Ertem, U. (2017) · Gazi Medical Journal · doi:10.12996/gmj.2017.50 · Cited by 2
“A familial cancer tendency can be an important risk factor in the development of both primary and secondary malignancies in children (14-19).”
BackgroundCabañuz, M. A., Bretón, M. D., Ezquerro, J. C., del Amo, M. D. A., & Sánchez, A. T. G. (2020) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2020.11.009 · Cited by 2
Risk-reducing mastectomy in mutation carriers
Zaborowski, A. M., & Boland, M. R. (2024) · British journal of surgery · doi:10.1093/bjs/znae264 · Cited by 2
Breast cancer inBRCAmutation carriers: breast-conserving therapy or bilateral mastectomy?
Murphy, J. O., & Sacchini, V. (2013) · Clinical Practice · doi:10.2217/cpr.13.72 · Cited by 2
Management of BRCA mutation carriers
Paris, I., Giorgio, D. D., Palluzzi, E., Garganese, G., Terribile, D. A., Fragomeni, S. M., D’Archi, S., Scambia, G., & Masetti, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.01.23 · Cited by 1
Rugo, H. S., Majure, M. C., Dragun, A. J., Buxton, M., & Esserman, L. J. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm109 · Cited by 2
Friedman, D. L. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00062-x · Cited by 2
van der Sangen, M. J. C. (2013) · doi:10.26481/dis.20131127ms · Cited by 2
Michaelson‐Cohen, R., Beeri, R., Golomb, E., & Levy‐Lahad, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_22 · Cited by 1
Hereditary breast and ovarian cancer – University Hospital of Split experiences
Miše, B. P., Katalenić, M., Hrepić, D., Kuret, S., & Hofman, I. D. (2023) · Libri Oncologici Croatian Journal of Oncology · doi:10.20471/lo.2023.51.01.02 · Cited by 1
“A prospective cohort study with more than 2,000 BrCam breast cancer patients found that the risk of contralateral breast cancer 20 years after initial breast cancer diagnosis was 40% for BRCA1 and 26% for BRCA2(9).”
Lin, J., Lin, Z., Chen, Y., Wang, X., Huang, Y.-F., Zhang, H., Zhu, L. F., Xu, Z., Gao, X., Zhang, Y., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2493769 · Cited by 1
“Germline mutations and somatic mutations are common and variable in oncological diseases, which may lead to the occurrence and contribute to the pathogenesis of MPMTs. Mutations in BRCA1 and BRCA2 are associated with high risks of second primary breast cancer or ovarian cancer [10].”
Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers
Maxwell, K. N., & Domchek, S. M. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0086-4 · Cited by 1
Self-citationAssessing, Counseling, and Treating Patients at High Risk for Breast Cancer
Clifford, E., Hughes, K. S., Roberts, M. E., Pirzadeh-Miller, S. M., & McLaughlin, S. A. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5399-5 · Cited by 1
“If the same patient had two or more first-degree relatives with breast cancer, the CBC risk was 68 %.(29)”
BackgroundScreening and Prevention of Ovarian Cancer
Kobayashi, H. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-4160-0_4 · Cited by 1
Prophylactic Mastectomy and Breast Reconstruction in Patients at High Risk for Breast Cancer
Chu, C. K.-C., & Bedrosian, I. (2020) · Current Breast Cancer Reports · doi:10.1007/s12609-020-00355-2 · Cited by 1
Analysis of bilateral breast carcinomas
Pasetto, C. V., Batista, B. R., Budel, L. R., Andreoli, M. D. N., & Budel, V. M. (2021) · Mastology · doi:10.29289/2594539420200026 · Cited by 1
Kiechle, M. B., & Grill, S. (2021) · Journal für Gynäkologische Endokrinologie/Schweiz · doi:10.1007/s41975-021-00192-1 · Cited by 1
Management of Hereditary Breast Cancer: An Overview
Kattepur, A. K., & Gopinath, K. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_18 · Cited by 1
Larionov, A. A., Fewings, E., Redman, J., Goldgraben, M. A., Clark, G. R., Boice, J. D., CONCANNON, P. J., Bernstein, J. L., Conti, D. V., the WECARE Study Collaborative Group, et al. (2023) · Cancers · doi:10.3390/cancers15020415 · Cited by 1
“5% per year after diagnosis of the first BC [24], which is at least five times higher than in non-carriers [2,3].”
BackgroundGenetic Risk Prediction in Breast Cancer
Nguyen, A., Plichta, J. K., Cintolo-Gonzalez, J., Kartal, K., Griffin, M., & Hughes, K. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-60336-0_15 · Cited by 1
Düzkale, N., & Teker, H. T. (2021) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0026 · Cited by 1
“In another study, 10-year contralateral breast cancer risk in BRCA1 carriers was reported to be 24%, and the same risk for BRCA2 carriers was 19% [6].”
BackgroundKiechle, M. B., & Grill, S. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04662-8 · Cited by 1
Manturova, N. E., Mistakopulo, F. N., Зикиряходжаев, А. Д., Portnoy, S. M., Sobolevskiy, V. A., Крохина, О. В., & Sukhotko, A. S. (2020) · Plastic Surgery and Aesthetic Medicine · doi:10.17116/plast.hirurgia20200415 · Cited by 1
Surgical Options for Primary Prevention: Prophylactic Mastectomy and Oophorectomy
Murphy, J. O., & Sacchini, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_18 · Cited by 1
Genetic/Familial High-Risk Screening: MRI Alone?
Marino, M. A., Clauser, P., & Helbich, T. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-41207-4_10 · Cited by 1
Present Options in the Prevention of Breast Cancer
Russo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-72815-1_7 · Cited by 1
Lee, M. K., & Robson, M. E. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad129 · Cited by 1
Knowledge, Attitudes, and Utilization of BRCA Testing Among Obstetricians and Gynecologists
Nassef, S. A. (2012) · Digital Commons-TMC (Texas Medical Center)
Predictors of Contralateral Breast Cancer in BRCA Negative Women
Simmons, A. (2012) · Digital Commons-TMC (Texas Medical Center)
Gynecologic Considerations for Women with Breast Cancer
Robinson, W. R., & Ali, K. F. (2014) · Springer eBooks · doi:10.1007/978-81-322-0843-3_18
Critique of “Evidence-Based Surgical Hypothesis: The case against BRCA1 and 2 testing”
Nussbaum, R. L. (2012) · Surgery · doi:10.1016/j.surg.2011.12.030
Gutowski, M. (2013)
Risk-Reducing Surgery for Breast Cancer Patients with BRCA Mutations
Kim, E., Kim, S., & Noh, D. (2016) · Springer eBooks · doi:10.1007/978-4-431-55552-0_1
MODERN VIEWS ON BILATERAL BREAST CANCER
Fesik, Y. A., Krakhmal, N. V., Zavyalova, M. V., Михайлович, П. В., Slonimskaya, Y. M., & Vtorushin, S. V. (2014) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2014-5-160-168
Follow Up of Patients with Germline Mutations in High Risk Predisposition Genes
Kemp, Z. (2016) · Springer eBooks · doi:10.1007/978-3-319-41858-2_5
Medical Management of Breast Cancer in BRCA Mutation Carriers
Bayraktar, S., & Arun, B. (2017) · Springer eBooks · doi:10.1007/978-3-319-59198-8_8
Risk-Reducing Surgery for BRCA1/2 Genetic Mutation Carriers
O’Donoghue, C., Orcutt, S. T., Pal, T., & Laronga, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-59198-8_4
Surgical Management of Breast Cancer in BRCA Mutation Carriers
Cronin, P. A., & Cody, H. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-59198-8_7
Metadata
- Authors
- Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., Foulkes, W. D., Rosen, B., Sun, P., & Narod, S. A.
- Affiliations
- University of Toronto (CA)
- Creighton University (US)
- Centre Hospitalier de l’Université de Montréal (CA)
- Beth Israel Deaconess Medical Center (US)
- University of Chicago (US)
- University of Pennsylvania (US)
- University of California, San Francisco (US)
- Sunnybrook Health Science Centre (CA)
- McGill University (CA)
- University Health Network (CA)
- Women’s College Hospital Research and Innovation Institute (CA)
- Corresponding author
- Narod, S A
- Venue
- British Journal of Cancer
- Published
- 2011-04
- Volume
- 104
- Issue
- 9
- Pages
- 1384-1392
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC3101934
- OpenAlex
- W2002561481
- Cited by
- 232
- References
- 15
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 15 · 2021: 21 · 2020: 31 · 2019: 13 · 2018: 9 · 2017: 12 · 2016: 17 · 2015: 20 · 2014: 18 · 2013: 21 · 2012: 16
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- contralateral breast cancer, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, oophorectomy, age at diagnosis, family history (medicine), first-degree relatives, early-onset breast cancer, risk factors, young women
- MeSH terms
- Adult, Age Factors, Aged, Breast Neoplasms, Female, Heterozygote, Humans, Middle Aged, Mutation, Ovariectomy, Predictive Value of Tests, Risk Factors, Cohort Studies, Odds Ratio, Survival Analysis, Neoplasms, Second Primary, Risk Assessment, Genes, BRCA1, Genetic Predisposition to Disease, Genes, BRCA2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
